Article

From ASCO: Updates in HER2-positive breast cancers

Author(s):

Debu Tripathy

Debu Tripathy blog image

Debu Tripathy, MD, editor-in-chief of CURE, discusses preliminary studies on combining Herceptin (trastuzumab) with existing drugs to treat HER2-positive breast cancer. These highlighted studies were presented at the 2013 American Society of Clinical Oncology's annual meeting in Chicago.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of doctor.
Image of man with black hair.
Picture of Dr. Pouneh Razavi
Richard Winneker gathers input from patients and researchers to shape MPN research, aiming to fund strategic projects for this population.
Dr. Curtiland Deville Jr. discusses the importance of crafting an individualized treatment plan for patients with prostate cancer.
Image of man.
Image of Crispino
Image of Dr. Reznick
Picture of Joy Anderson
Some patients with relapsed/refractory diffuse large B-cell lymphoma whose disease progressed after CAR-T cell therapy, responded to odronextamab.
Related Content
Illustration of Chester
May 1st 2025

Teddy Bears are a Good Therapy for Adults with Cancer

Chester Freeman
Teddy bears offer emotional comfort and connection for adults with cancer, easing anxiety and fostering trust during treatment.
The Importance of Spotting Endometrial Cancer
March 18th 2025

The Importance of Spotting Endometrial Cancer

Endometrial cancer is on the rise. Hear survivor Angélica and Eisai Inc.'s Teresa Cronin discuss the Spot Her® initiative, which empowers women to spot early signs. This episode is sponsored by Eisai.
A phase 1 trial has initiated and is investigating treatment with ziftomenib plus Gleevec in advanced GIST: © stock.adobe.com.
May 1st 2025

First Patient Dosed in Trial of Ziftomenib for Advanced GIST

Spencer Feldman
A phase 1 trial has initiated and is investigating treatment with ziftomenib plus Gleevec in advanced GIST following progression on Gleevec.
ROS1+ Non-Small Cell Lung Cancer: Progress in Care
September 20th 2024

ROS1+ Non-Small Cell Lung Cancer: Progress in Care

This episode of the Cancer Horizons podcast features Dr. Jason Porter – a medical oncologist and hematologist at the West Cancer Center and Research Institute and Director of the Lung Cancer Disease research group and is sponsored by Bristol Myers Squibb.
Image of breast.
April 30th 2025

FDA Completes Review of Hepzato Combo in HER2– Metastatic Breast Cancer

Ryan Scott
The FDA has completed its 30-day review of an application for Hepzato in combination with standard of care in liver-dominant metastatic breast cancer.
Image of bladder.
April 30th 2025

Aidixi Plus Bacillus Calmette-Guérin Effective in Bladder Cancer

Jason M Broderick
Aidixi plus BCG showed strong early efficacy and manageable safety in patients with high-risk, HER2-expressing non–muscle-invasive bladder cancer.